Bifunctional energy-reversible acyl-compositions

1. A compound of the formula:

wherein:

R 1 and R 2 are individually selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched;

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkenyls or C 2 -C 10 heteroalkynyls and —(CR 15 R 16 ) p -D;

wherein:

R 15 and R 16 are individually selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched; and

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkenyls or C 2 -C 10 heteroalkynyls;

p is a positive integer from 1 to about 12;

D is selected from the group consisting of —SH, —OH, X 2 , —CN, —OR 19 , NHR 20 ,

wherein:

R 17 is H, CH 3 or X 3 ;

R 18 is H, a C 1-4 alkyl or benzyl;

R 19 is H, a C 1-4 alkyl, X 2 or benzyl;

R 20 is H, a C 1-10 alkyl or —C(O)R 21 ,

wherein

R 21 is H, a C 1-4 alkyl or alkoxy, t-butoxy or benzyloxy;

X 2 and X 3 are independently selected halogens;

R 3 is H, CH 3 , or —C(═O)(CR 15 R 16 ) w -D,

where w is 0 or an integer from 1 to about 12, and D is H or as described for R 1 and R 2 ;

J is O, NH or S;

R 4 , R 5 , and R 6 are independently selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched; C 2 -C 10 heteroalkyls, heteroalkenyls or heteroalkynyls and halogens;

Z is NR 7 R 8 or

wherein

R 7 is selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, alkenyls or alkynyls straight or branched; C 2 -C 10 heteroalkyls, heteroalkenyls or heteroalkynyls, or —(CR 23 R 24 ) q -aryl, or R 8 ,

wherein

R 23 and R 24 are independently selected from the group consisting of H and C 1 -C 10 alkyls;

q is an integer from 1 to about 6;

R 8 is selected from the group consisting of (CR 9 R 10 ) n -NR 22 -R 11 , (CR 9 R 10 ) n -CH 2 -NHC(O)R 26 and (CR 9 R 10 ) n -CH 2 -E;

wherein

R 9 and R 10 are independently selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched;

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkenyls or C 2 -C 10 heteroalkynyls and halogens;

R 26 is H, CH 3 , O-t-butyl, O-benzyl;

E is OH, SH or O—C(O)R 27 ,

wherein R 27 is a C 1 -C 6 alkyl, benzyl or phenyl;

R 22 is H or CH 3 ;

n is a positive integer from 1 to about 10;

R 11 is H or-L-B,

wherein

L is a positive linker covalently linking NR 22 to B; and

B is selected from the group consisting of polymers, biologically active materials and polymeric supports;

R 25 is H, —C(O)—R 28 or —C(O)—O—R 29 ,

wherein R 28 is a C 1 -C 6 alkyl or benzyl; and R 29 is CH 3 , t-butyl or benzyl;

X 1 is O, NH, or S; and

A is A 2

wherein X 1 A 2 is an enzyme, or a pharmaceutical salt thereof.

2. The compound of claim 1 , wherein Z is NR 7 R 8 .

3. The compound of claim 2 , wherein R 8 is —CH 2 —CH 2 —NH 2 .

4. The compound of claim 2 , wherein R 8 is (CR 9 R 10 ) n —NR 22 —R 11 .

5. The compound of claim 1 , wherein L-B is a maleimidyl or an N-hydroxysuccinimidyl compound.

6. The compound of claim 4 , wherein R 11 is a polyalkylene oxide residue.

7. The compound of claim 6 , wherein said polyalkylene oxide residue is a polyethylene glycol.

8. The compound of claim 7 , wherein said polyethylene glycol has a number average molecular weight of from about 2,000 to about 200,000 daltons.

9. The compound of claim 4 , wherein R 11 is a member of the group consisting of collagen, glycosaminoglycan, poly(-aspartic acid), poly(-L-lysine), poly(-lactic acid), poly-N-vinylpyrolidone and copolymers of poly(-lactic acid) and poly(-glycolic acid).

10. The compound of claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of H, CH 3 and CH 3 CH 2 .

11. The compound of claim 4 , wherein R 7 is CH 3 CH 2 ; R 8 is —(CR 9 R 10 ) n —NR 22 —R 11 ; and R 9 and R 10 are H; n is 2; and X 1 is O, S or NH.

12. The compound of claim 4 , wherein R 7 is CH 3 CH 2 ; R 8 is —(CR 9 R 10 ) n —NR 22 —R 11 and R 9 and R 10 are H.

13. The compound of claim 1 , wherein A 2 is an enzyme selected from the group consisting of serine proteases, cysteine proteases, esterases, lipases and enzymes containing an active-site serine or cysteine.

14. The compound of claim 1 , wherein J is O, R 2 is H, R 7 is CH 3 CH 2 ; R 8 is -(CR 9 R 10 ) n -NR 22 -R 11 , R 9 and R 10 are H, and n is 2.

15. The compound of claim 13 , wherein X 1 A 2 is an enzyme having an active-site serine or cysteine.

16. The compound of claim 1 , wherein X 1 A 2 is a blood coagulation factor.

17. The compound of claim 1 , wherein the enzyme is selected from the group consisting of plasmins, urokinases, and tissue plasminogen activators.

18. A compound of claim 1 selected from the group consisting of;

19. A method of treatment, comprising:

administering to a mammal in need of such treatment an effective amount of a compound of formula (I)

wherein;

R 1 and R 2 are individually selected from the group consisting of H, CH 3. C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls. straight or branched;

C 2 -C 10 heteroalkyls. C 2 -C 10 heteroalkenyls or C 2 -C 10 heteroalkynyls and -(CR 15 R 16 ) p -D;

wherein:

R 15 and R 16 are individually selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls straight or branched; and

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkenyls or C 2-C 10 heteroalkynyls;

p is a positive integer from 1 to about 12;

D is selected from the group consisting of—SH, —OH, X 2 , —CN, —OR 19 , NHR 20 ,

wherein:

R 17 is H, CH 3 or X 3 ;

R 18 is H, a C 1-4 alkyl or benzyl;

R 19 is H, a C 1-4 alkyl, X 2 or benzyl;

R 20 is H, a C 1-10 alkyl or —C(O)R 21 ,

wherein

R 21 is H. a C 1-4 alkyl or alkoxy, t-butoxy or benzyloxy;

X 2 and X 3 are independently selected halogens;

R 3 is H, CH 3 , or —C(=O)(CR 15 R 16 ) w -D,

where w is 0 or an inteiler from 1 to about 12, and D is H or as described for R 1 and R 2 ;

J is O, NH or S;

R 4 , R 5 , and R 6 are independently selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls. C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched; C 2 -C 10 heteroalkyls, heteroalkenyls or heteroalkynyls and halogens;

Z is NR 7 R 8 or

wherein

R 7 is selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, alkenyls or alkynyls straight or branched; C 2 -C 10 heteroalkyls, heteroalkenyls, or heteroalkynvis, or -(CR 23 R 24 ) q -aryl, or R 8 ,

wherein

R 23 and R 24 are independently selected from the group consisting of H and C 1-C 10 alkyls;

q is an integer from 1 to about 6;

R 8 is selected from the group consisting of (CR 9 R 10 ) D -NR 22 -R 11 , (CR 9 R 10 ) n -CH 2 -NHC(O)R 26 and (CR 9 R 10 ) n -CH 2 -E;

wherein

R 9 and R 10 are independently selected from the group consisting of H, CH 3 , 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched;

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkynyls and halogens;

R 26 is H, CH 3 , O-t-butyl, O-benzyl;

E is OH, SH or O—C(O)R 27 ,

wherein R 27 is a C 1 -C 6 alkyl, benzyl or phenyl;

R 22 is H or CH 3 ;

n is a positive integer from 1 to about 10;

R 11 is H or -L-B,

wherein

L is a linker covalently linking NR 22 to B; and

B is selected from the group consisting of polymers. biologically active materials and polymeric supports;

R 25 is H, —C(O)-R 28 or —C(O)-R 29 ,

wherein R 28 is a C 1- C 6 alkyl or benzyl; and R 29 is CH 3 , t-butyl or benzyl;

X 1 is O,NH, or S; and

A is A 2

wherein X 1 A 2 is an enzyme, or a pharmaceutical salt thereof.

20. The method of claim 19 , further comprising exposing the compound of formula (I) to an energy source after administration to said mammal.

21. The method of claim 20 , wherein the energy source is white light having a wavelength in the range from 340 to 700 nm.

22. The method of claim 20 , wherein the energy source is white light having a wavelength in the range from 350-420 nm.

23. The method of claim 20 , wherein the energy source is selected from the group consisting of microwave, ultrasound, radio energy, gamma radiation, radioactivity, ultraviolet light and infrared light.

24. A method of preparing a conjugate, comprising;

reacting a compound of Formula (IV)

wherein:

R 1 and R 2 are individually selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched;

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkenyls or C 2 -C 10 heteroalkynyls and —(CR 15 R 16 ) p -D

wherein:

R 15 and R 16 are individually selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls and C 2 -C 10 alkynyls, straight or branched; and

C 2 -C 10 heteroalkyls, C 2 -C 10 heteroalkenyls or C 2 -C 10 heteroalkynyls;

p is a positive integer from 1 to about 12;

D is selected from among —SH, —OH, X 2 , —CN, —OR 19 , NHR 20 ,

wherein:

R 17 is H, a CH 3 or X 3 ;

R 18 is H, a C 1-4 alkyl or benzyl;

R 19 is H, a C 1-4 alkyl, X 2 or benzyl;

R 20 is H, a C 1-10 alkyl or —C(O)R 21

wherein

R 21 is H, a C 1-4 alkyl or alkoxy, t-butoxy or benzyloxy;

X 2 and X 3 are independently selected halogens;

R 3 is H, CH 3 , or —C(═O)(CR 15 R 16 ) w -D,

where w is 0 or an integer from 1 to about 12, and D is H or as described for R 1 and R 2 ,

J is O, NH or S;

R 4 , R 5 and R 6 independently selected from the group consisting of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkenyls or C 2 -C 10 alkynyls, straight or branched;

C 2 -C 10 heteroalkyls, heteroalkenyls or heteroalkynyls and halogens;

R 7 is selected from among H, CH 3 and C 2 -C 10 alkyls;

R 9 and R 10 are independently selected from the group of H, CH 3 , C 2 -C 10 alkyls, C 2 -C 10 alkynyls, straight or branched; C 2 -C 10 heteroalkyls, C 2 -C 10 heteroakynyls, and halogen;

n is a positive integer from 1 to 10;

X 1 is O, NH, or S;

R 22 is H or CH 3 ; and

A is A 2

wherein X 1 A 2 is an enzyme

with a compound of the Formula (V):

L 1 −B 1   (V)

wherein

L 1 is a moiety containing a functional group capable of reacting with the NHR 22 of Formula (IV); and

B 1 is selected from the group consisting of polymers, biologically active materials and polymeric supports.

25. The method of claim 24 , wherein L 1 -B 1 includes a member selected from the group consisting of heterobifunctional reagents having N-hydroxysuccinimide and maleimide, bifunctional maleimide and bifunctional polyethylene glycol.

26. The method of claim 25 , wherein the heterobifunctional reagent is Succinimidyl-6-[(β-maleimidopropionamido) hexanoate].

27. The compound of claim 1 , wherein L-B is selected from the group consisting of heterobifunctional reagents having N-hydroxysuccinimide and maleimide, bifunctional maleimide and bifunctional polyethylene glycol.

28. The compound of claim 7 , wherein said polyethylene glycol is bifunctional polyethylene glycol.

29. The compound of claim 16 , wherein X 1 A 2 is selected from the group consisting of thrombin (Factor IIa), Factor VIIa, Factor IXa, Factor Xa, Factor XIa and Factor XIIa.

30. The compound of claim 1 , wherein L is a linker selected from the group consisting of succinimides, maleimides, imidoesters, 2-iminothiolanes, hydrazides, maleic anhydrides, azides, citraconic anhydrides and glutaraldehydes.

31. The compound of claim 1 , wherein B is selected from the group consisting of antibodies, fragments thereof, single chain binding antibodies, monoclonal antibodies, growth factors, interferons, cytokines, cell-surface binding metabolites, lectin, sugar-peptide, sugar-petide-lipid targeting agents, proteins, nucleic acids, lectins, lipids, carbohydrates, inhibitors of cell surface enzymes, PAOs, glycosaminoglycans, dextran, poly-glutamic acid, poly-aspartic acid, poly-L-lysine and mixtures thereof, polyvinylpyrrolidine, collagen, peptides, hormones, ligands for receptors, and carriers and supports in form of columns, films, membranes, beads, particles, microparticles, and filters.